Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Galapagos Presents Superior Potentiator Series for CF

Published: Friday, October 18, 2013
Last Updated: Friday, October 18, 2013
Bookmark and Share
Novel proprietary series to start clinical trials end of 2014.

Galapagos NV has developed a series of novel potentiators in its cystic fibrosis program. The data will be presented at the North American Cystic Fibrosis Conference taking place from 17 - 19 October in Salt Lake City, Utah.

In its CF research program, Galapagos developed novel potentiator series that are highly potent and that show superior opening of the defective CFTR channel in comparison to Kalydeco®.

This was shown in assays of cells that carry a CFTR class II, III or IV mutation. Furthermore, the superior channel opening was confirmed in primary cells from F508del and G551D patients.

In addition to its efficacy, the Galapagos series show good metabolic stability and permeability and favorable PK profiles. In comparison to Kalydeco®, the new potentiators have a superior in vitro safety profile, including a clean CYP profile and high selectivity.

These results encourage Galapagos to nominate a pre-clinical candidate from this series at the end of this year, with the first clinical trials starting at the end of 2014. Galapagos has pending patents on these novel potentiators.

Galapagos initiated its research in CF in 2005 as part of a collaboration with the Cystic Fibrosis Foundation. In 2010 Galapagos decided to pursue CF as the first orphan disease in which the company is attempting to discover, develop and launch its own medicines.

In September 2013 Galapagos signed an agreement with AbbVie where they will work collaboratively to develop and commercialize oral drugs that address the main mutations in CF patients, including F508del and G551D.

Galapagos will present its novel potentiators at a poster session (abstract #41) at NACFC on 17 October at 11:50 am and 18 October at 4 pm.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Galapagos Completes Recruitment for ORIGIN Phase 2 Trial
Recruitment for the Phase 2 Proof-of-Concept study with GPR84 inhibitor GLPG1205 in ulcerative colitis patients.
Saturday, June 20, 2015
Galapagos DARWIN 1 and 2 Studies have Completed 24 Weeks of Treatment
Topline results from final analyses expected to be released in July and August 2015.
Thursday, June 11, 2015
Galapagos Regains Rights to GLPG1690
Filing for Phase 2 clinical trial in 2015.
Thursday, March 19, 2015
Galapagos Receives €1.6 Million IWT Grant for Hepatitis B Program
Research will focus on compounds against viral protein targets and on inhibitors of host cell proteins.
Thursday, February 12, 2015
Galapagos Receives €2.5 Million IWT Grant for Antibiotic Research
Grant to support the development of Galapagos’ novel antibiotics in a collaboration project.
Saturday, January 24, 2015
Galapagos Completes Recruitment for Darwin 2 Monotherapy Study
Study will begin a series of topline readouts starting around end of the first quarter 2015.
Monday, November 24, 2014
Galapagos Presents Favorable Phase 1 Data for IBD Target
Galapagos NV discloses GPR84 as a promising novel target for treating inflammatory bowel disease during an oral presentation at United European Gastroenterology Week in Vienna.
Tuesday, October 21, 2014
Bart Filius Joins Galapagos as CFO
Bart will join the Executive Committee of Galapagos and be responsible for Finance, Investor Relations, IT, and Purchasing.
Saturday, October 18, 2014
Galapagos Receives Milestone in Osteoarthritis Alliance with Servier
Company completes the nomination of new pre-clinical candidate in the alliance with Servier.
Thursday, August 07, 2014
Galapagos Receives €2 Million from Osteoarthritis Alliance with Servier
Company is responsible for discovery and development of new candidate drugs.
Tuesday, March 11, 2014
Galapagos Receives €2.3 Million IWT Grant for Fibrosis Research
Aim of IWT grant is to deliver a comprehensive fibrosis research platform.
Tuesday, February 04, 2014
Galapagos Receives €2.9 Million IWT Grant for Cystic Fibrosis Research
Project to identify and progress multiple promising CF therapies towards pre-clinical candidates.
Monday, January 13, 2014
Galapagos Selects Pre-Clinical Candidate for Cystic Fibrosis
Start of Phase 1 expected before end 2014.
Tuesday, December 17, 2013
Galapagos Reports Positive Phase 1 Results for GLPG1205
Company is developing GLPG1205 within its alliance with Janssen Pharmaceutica NV.
Wednesday, December 04, 2013
Galapagos Subsidiary BioFocus Signs Agreement with Biogen Idec in Scleroderma
Will leverage Galapagos' SilenceSelect® platform and unique human skin models.
Monday, November 18, 2013
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
How To Keep Your Rice Arsenic-Free
Researchers at Queen’s University Belfast have made a breakthrough in discovering how to lower worrying levels of arsenic in rice that is eaten all over the world.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Computer Model Could Explain how Simple Molecules Took First Step Toward Life
Two Brookhaven researchers developed theoretical model to explain the origins of self-replicating molecules.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!